Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.

ABSTRACT:

Background

There is accumulating evidence that propranolol, an antagonist of beta-1 and beta-2 adrenoreceptors, extends survival of patients with prostate cancer; yet it is not known whether propranolol inhibits beta-adrenergic signaling in prostate cancer cells, or systemic effects of propranolol play the leading role in slowing down cancer progression. Recently initiated clinical studies offer a possibility to test whether administration of propranolol inhibits signaling pathways in prostate tumors, however, there is limited information on the dynamics of signaling pathways activated downstream of beta-2 adrenoreceptors in prostate cancer cells and on the inactivation of these pathways upon propranolol administration.

Methods

Western blot analysis was used to test the effe

SUBMITTER: Alaskar A 

PROVIDER: S-EPMC10100053 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature